条条大路通罗马？

shiweibuyi

原帖由 fromdesert34 于 2010-4-5 22:13 发表
楼主我有个疑问。
一下是摘自亚太会议上面有关rep9ac的文章中提到了最长的一例持续性应答为八周之久。。而你的那篇文摘中的怎么说所有六例病人的持续性应答都已经达到半年之久了？
Preliminary Evidence of Rapid HBsA ...

根据来源，可能1人，也可能6人。

“Interim data on the efficacy of the amphipathic DNA polymer REP 9AC in the treatment of chronic hepatitis B in 6 patients will be presented. Interim results will show that REP 9AC treatment rapidly leads to the detection of anti-HBsAg antibodies and the reduction and or clearance of serum HBsAg within the first 12 weeks of treatment in human patients. These findings are associated with substantial and sustained reductions in serum HBV titers which may be due to an improved immune response to the infection. This is exemplified by the first patient who had 2,000,000 copies of the virus / ml in his blood, was then treated for a total of 23 weeks and who has so far maintained a sustained virologic response (<70 copies of the virus / ml in his blood) for a period of 6 months off treatment.”

富贵数字

原帖由 shiweibuyi 于 2010-4-6 10:11 发表


根据来源，可能1人，也可能6人。

“Interim data on the efficacy of the amphipathic DNA polymer REP 9AC in the treatment of chronic hepatitis B in 6 patients will be presented. Interim results will show t ...

为什么说可能啊？

fromdesert34

我昨天发邮件询问了Michel Bazinet, MD此药物的具体信息。。今天就给回复了。回复如下。本人英文水平有限抱着试试的态度发的。没想到回了。大家给具体翻译下。


Thank you for your interest in our drug. We are still early in the clinical trial and cannot release much information yet. Our drug interacts with surface antigen (HBsAg) and prevents its release from infected hepatocytes. This results in a gradual reduction of surface antigen in the blood. Many scientific papers have suggested that surface antigen suppresses the immune response to the virus and allow the infection to be chronically maintained in the liver. By eliminating the surface antigen from the blood, it appears that we allow the immune system to mount an effective response against the virus and this can result in a clearance of the viral infection from the liver. In other words, by removing the surface antigen from the blood, we give the patient the ability to fight his hepatitis B infection on his own.

The interaction between our drug and surface antigen occurs over a large surface area.  Therefore, resistance to the drug will be very unlikely.

It is too early to comment on side effects since we have treated only a few patients but it appears that the drug will be much easier to tolerate than interferon.

We do not have approval to do a clinical study in China at this time.

We are trying to go as fast as possible to bring this drug to patients but it will likely take a few years before it is approved and available for use. We are currently trying to raise funds to accelerate the recruitment of patients in our clinical trial.

The best way you can understand the potential of our drug is by understanding the importance of surface antigen in suppressing the ability of the immune response to fight the infection. I have listed below some of the scientific references that discuss this topic (many of these papers were published by Chinese scientists). These papers are very technical in nature but there might be scientists in your group that can understand them.

Best regards.

肝胆相照009

Replicor公司的回信
Thank you for your interest in REPLICor’s hepatitis B drug.

Please checkout our latest press release on our progress in developing our technology for the treatment of hepatitis B here: http://www.replicor.com/debut_anglais2.htm and select “News”.

The press release provides an up to date summary of how patients are progressing on the REP 9AC treatment.

Regards,
________________________________
Andrew Vaillant, Ph.D.
Vice President and CSO
REPLICor Inc.
6100 Royalmount Avenue, Suite D-101
Montreal  Quebec  Canada H4P 2R2
[email protected]
(514) 496-9011 (office)
(514) 496-9021 (fax)
(514) 862-2271 (mobile)
This message and any attachments are confidential and for the intended recipients only.

自杀未遂

看了回信
大致就是说此药物是激发人体免疫来清除病毒，现在只是做了针对少数人的实验，大规模的正式人体实验还需数年。
信中并没有透露太多

fromdesert34

大家帮忙想想怎么用英文问他我上面问的问题啊。。我的英文水平不够好。。。

问题如下：
前面的内容已经他说了所有的病人已经清除了表抗原和产生表抗体了。。那为什么后面又说投稿前有一个已经产生持续性的病毒学应答？（乙肝病毒脱氧核糖核酸 - 乙肝表面抗原 - e抗原 - 抗- HBs +，抗- HBe +）到底是所有的都消除了表抗和产生抗体了还是就一个？
问题二：在http://www.replicor.com/debut_anglais2.htm这里面

news中写到了所有病人的持续性应答都已经达到半年了而在apasl上发布的却只有8周

lemonades

他的意思是表面抗原抑制了免疫系统，使感染能在肝脏内长期存在。他们的药物能够清除血液中的表面抗原，使免疫系统能够自己清除病毒。

今天分加完了，明天再给楼上各位加分。

Interferon

中心思想包括以下几条
：
1.        目前不宜透漏太多信息
2.        药物是作用于表面抗原，防止抗原从被感染的肝细胞中释放出来，并导致血清内抗原含量逐步减少，很多研究已经发现表面抗原抑制对病毒的免疫反映，这种抑制过程导致了慢性化，只要减少血清内的表面抗原，就能激活免疫反映以至于清除肝脏内的病毒感染。
3.        基本不会发生耐药
4.        现在评价副作用为时过早，患者耐受性良好
5.        目前未被许可在中国进行临床试验
6.        俺们也想快点，但是还得等几年（批准用于临床），正在试图追加预算用于招募志愿者
7.        你要想了解俺们的药，我建议你多看点关于表面抗原抑制免疫反映的参考材料，我都给你列出来了。

fromdesert34

原帖由 lemonades 于 2010-4-6 11:57 发表
他的意思是表面抗原抑制了免疫系统，使感染能在肝脏内长期存在。他们的药物能够清除血液中的表面抗原，使免疫系统能够自己清除病毒。

今天分加完了，明天再给楼上各位加分。 ...

柠檬能否回答我的问题啊。。他的那六例表面抗原阳性的人既然全部都转为阴性以及产生表抗体了为什么说目前为止就一个人产生了持续性应答？

lemonades

因为他写的是第一位病人产生了持久性应答。意味着其他五位病人应用时间不长，即使已经停药，也没有第一个病人停药时间长。